NCT02764476

Brief Summary

The purpose of this study is to design and test the safety and feasibility of virtual reality technologies and experiences of egocentric avatar embodiment in the application of physical and cognitive behavior therapy in functional neurological symptom/conversion disorder. Investigators hypothesize that patients will safely use and accept this modality of treatment and will show evidence of a decrease in symptom frequency.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2016

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 2, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 6, 2016

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

August 30, 2023

Status Verified

August 1, 2023

Enrollment Period

5.6 years

First QC Date

May 2, 2016

Last Update Submit

August 28, 2023

Conditions

Keywords

psychogenicnon-epileptic seizuresfunctional neurological symptom disorderPNESPMDvirtual reality3D augmented realitymirror therapy

Outcome Measures

Primary Outcomes (1)

  • Adherence

    Number of sessions attended over 12 weeks recorded by therapist

    Number of sessions attended over 12 weeks

Secondary Outcomes (7)

  • General Self-Efficacy Scale

    baseline, biweekly for 6weeks, then 6,9,12 months

  • Global Assessment of Functioning (GAF)

    baseline, 6weeks, then 6,9,12 months

  • Generalized Anxiety Disorder 7-item (GAD-7) scale

    baseline, biweekly for 6weeks then 6,9,12 months

  • Patient Health Questionnaire-9 (PHQ-9)

    baseline, biweekly for 6weeks then 6,9,12 months

  • Oxford Handicap Scale

    baseline, 6weeks, then 6,9,12 months

  • +2 more secondary outcomes

Study Arms (2)

Virtual Reality Therapy

EXPERIMENTAL

Eight 30 minute sessions of embodied virtual reality therapy with use of a body transfer experience into an egocentric perspective avatar that encourages motor activity and desensitization to emotional cues.

Other: Embodied Virtual Reality Therapy

Control

ACTIVE COMPARATOR

Eight 30 minute sessions of virtual reality therapy.

Other: Virtual reality

Interventions

Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.

Virtual Reality Therapy

Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults 18-65 years, who are diagnosed with functional neurologic symptom or conversion disorder. If diagnosis of seizure type then video EEG with diagnosis confirmed by board-certified neurologist with subspecialty training in epilepsy and clinical neurophysiology using the criteria of the International Classification of the Epilepsies is required. If diagnosis of motor type, documented and clinically established levels of diagnostic certainty (Williams,1995) confirmed by 2 neurologists is required.
  • Participants must have at least one symptom per month in the month prior to enrollment
  • Fluency in English spoken language

You may not qualify if:

  • Nonfluency or inability to communicate in English spoken language
  • Inability to participate or attend biweekly 30 minute session over 14 weeks
  • Frank psychosis
  • Active self harm urges
  • Serious medical illness
  • Active substance or alcohol use or dependence that could interfere with participation
  • Diagnoses of mental retardation, dementia or delirium
  • Pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University

Stanford, California, 94010, United States

Location

Related Publications (1)

  • Bullock K, Won AS, Bailenson J, Friedman R. Virtual Reality-Delivered Mirror Visual Feedback and Exposure Therapy for FND: A Midpoint Report of a Randomized Controlled Feasibility Study. J Neuropsychiatry Clin Neurosci. 2020 Winter;32(1):90-94. doi: 10.1176/appi.neuropsych.19030071. Epub 2019 Nov 5.

Related Links

MeSH Terms

Conditions

Conversion DisorderSeizures

Condition Hierarchy (Ancestors)

Somatoform DisordersMental DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Kim D Bullock, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Single blinded randomized control trial for 8 weeks, then control group will be offered active treatment if desired.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

May 2, 2016

First Posted

May 6, 2016

Study Start

May 1, 2016

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

August 30, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations